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Abstract
Background: The MATRICS Consensus Cognitive Battery (MCCB) was developed for schizophrenia patients, but is
also being used to assess neurocognitive function in bipolar disorder. This study aims to describe neurocognitive
differences in major depressive disorder patients and healthy controls with the MCCB, and to describe the relationship
between depression symptom severity, subjective cognitive complaints, and objective cognitive test performance.
Methods: Thirty-three patients with major depressive disorder and 33 pairwise matched healthy controls were
assessed with the MCCB. The patients were also assessed with the Montgomery-Åsberg Depression Rating Scale
(MADRS) and the Everyday Memory Questionnaire (EMQ).
Results: On all neurocognitive domains, the depression patients scored significantly lower than the controls. The level
of impairment ranged from 21.0 % (Working Memory) to 58.0 % (Speed of Processing). There were significant
associations between neurocognitive test performance and depression symptom severity, but not with subjective
cognitive complaints.
Conclusions: The MCCB was applicable in this study of major depressive disorder, and revealed significant
neurocognitive dysfunction in this group. At least one fifth of the patients were impaired on all cognitive
domains, with Speed of Processing and Reasoning/Problem Solving being most strongly affected. The
objective test scores were significantly related to depression severity, but not to subjective cognitive complaints.
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Background
Mild to moderate cognitive dysfunction is a common
symptom in major depressive disorders (MDD). Speed
of processing, executive function, working memory, and
learning/short-term memory seem to be more strongly
affected than other functions [1–3]. Although some dif-
ferences between acute and remitted states have been
noted [1], mild cognitive impairment may be present in
recovered individuals as well [4].
The MATRICS Consensus Cognitive Battery (MCCB)
[5] is one of the most popular assessment batteries for
neurocognitive function in severe psychopathology. It
consists of 10 tests assessing 7 cognitive domains – Speed
of Processing, Attention/Vigilance, Working Memory,
Verbal Learning, Visual Learning, Reasoning/Problem
Solving, and Social Cognition. It was developed for the
schizophrenia population, but is also used with bipolar
disorder patients [6–9], and recently with MDD patients
[10]. Using a comprehensive battery consisting of highly
reliable and valid tests selected with respect to their toler-
ability in severely ill patients will facilitate comparison
across studies.
Studies comparing neurocognitive function, using tests
that assess similar domains as the MCCB does, have
found cognitive impairment in both schizophrenia and
depression disorders, but the level of impairment is
more severe in the former group [11–13]. In these stud-
ies, speed based tests scores and verbal memory func-
tions were most strongly affected. A similar pattern of
results was obtained in a recent study of MCCB
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performance in bipolar disorders [7]. Moreover, this study
demonstrated that the Norwegian version of the MCCB is
well tolerated and applicable in mood disorders [7].
As studies with the MCCB in other groups than
schizophrenia patients are scarce, there is little infor-
mation on the relationship between depression symp-
tom severity and test performance. In the bipolar
disorder study of Kessler et al. [7] symptom severity
was not correlated with MCCB test performance. A
similar finding of no significant association in depres-
sion patients tested with a battery that roughly corre-
sponds to the MCCB was reported by Rund et al.
[13]. However, processing speed alone has been found
to correlate with depression symptom load [14]. We
aim to study the same associations using the MCCB
in an MDD sample.
There is a well-known discrepancy between subjective
cognitive complaints (SCC) and objective test perform-
ance, both in individuals suffering from mental illness
[15] and healthy individuals [16, 17]. Usually, a person
may experience concentration problems and memory
lapses during work or activities of daily life, but still per-
form adequately during neuropsychological assessment.
For individuals suffering from MDD, this discrepancy
may be partly explained by the severity of the depressive
symptoms, as depression intensity is correlated with
SCC [18, 19]. In this study, we will describe the relation-
ship between SCC and MCCB performance.
Electroconvulsive therapy (ECT) for treatment-resistant
depression often results in a rapid decrease in symptoms.
However, a sizable minority of patients report reduced
cognitive function, at least during the first weeks after
treatment [20]. Despite cognitive side effects in some
patients, or fear of such in others, monitoring of post-
treatment cognitive function is not routinely performed
[21]. The lack of systematic and longitudinal monitoring
has made it impossible to ascertain how long the cognitive
side effects of ECT last. This paper is the first issued from
a 2-year longitudinal project on cognitive effects of elec-
troconvulsive treatment (ECT) for MDD in South-Eastern
Norway.
In the current paper, baseline neurocognitive function
in MDD is the main topic. Specifically, we aimed to
study neurocognitive differences in MDD and healthy
controls, and to describe the relationship between de-
pression symptom severity, subjective cognitive com-
plaints, and objective cognitive test performance.
Methods
Participants
Demographic data are presented in Table 1. The patient
group consisted of 33 participants with a major depres-
sive disorder recruited from the ECT clinical sections at
Vestre Viken Hospital Trust. All patients set to undergo
ECT and fulfilling the inclusion criteria of the project
were invited to participate. Less than ten eligible patients
declined. The patients were included from March 2011
to November 2014.
All patients were neurocognitively assessed 1–3 days
before the onset of ECT. Inclusion criteria were age
above 18 and below 70 years, capacity for giving in-
formed consent to both ECT and participation in this
project, ability to understand spoken and written
Norwegian, and a diagnosis of major depression epi-
sode resistant to other treatment methods. Exclusion
criteria were ongoing alcohol or drug abuse, previous
or ongoing neurological damage or illness, and ECT
within the last 2 years.
The diagnosis of a major depression episode was
established by clinical interviews by hospital staff ac-
cording to the DSM-IV criteria [22] and supported by
information from hospital records. Severity of depression
was assessed with the Montgomery-Åsberg Depression
Rating Scale [23]. Twenty-three of the patients were
diagnosed with recurrent unipolar depression and 10
with bipolar disorder type II. Seven had experienced
psychotic symptoms during depressive episodes, nine
had moderate to severe anxiety symptoms, and four
partially fulfilled the criteria for a personality disorder.
Five of the patients had been treated with 1–2 series
of ECT more than 2 years previously. All patients
had discontinued their psychotropic medication 1–7 days
before testing, although medication for anxiety and
insomnia had been permitted the evening before. Two
patients did not use any regular medication at inclu-
sion. See Table 2 for information on the daily doses
of medication [24].
The control group consisted of 33 healthy men and
women pairwise matched with the patient group on gen-
der, age, and level of education. The recruitment and as-
sessment procedure of the healthy controls have been
described in detail elsewhere [25, 26].
All participants signed an informed consent form be-
fore testing. This study was approved by the Regional
Committee for Research Ethics for Health Region
South-East (REK Sør-Øst).
Table 1 Demographic characteristics of the participants
Depression group (n = 33) Control group (n = 33)
Age 46.5 (10.6) 46.7 (10.9)
Gender 10 males, 23 females 10 males, 23 females
Education
Elementary school n = 10 (30.3 %) n = 8 (24.2 %)
High school n = 12 (36.4 %) n = 15 (45.5)
BA/BA + n = 11 (33.3 %) n = 10 (30.3 %)
Age in mean years (SD)
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Neuropsychological assessment
The cognitive assessment was carried out by a clinical
psychologist with extensive neuropsychological train-
ing (CM). The patients were tested at their respective
clinical wards, and the control group at the University
of Oslo or at the facilities of Vestre Viken Hospital
Trust.
All participants were tested with the MCCB, covering
the following seven domains [5, 27]: Speed of Processing
(Trail Making Test A; TMT-A [28], Symbol Coding;
Brief Assessment of Cognition in Schizophrenia, BACS
[29], and Fluency; Category Fluency [30]), Attention/
Vigilance (The Continuous Performance Test-Identical
Pairs; CPT-IP [31]), Working Memory (Spatial Span;
The Wechsler Memory Scale, SS-WMS [32] and Letter
Number Span; The University of Maryland Letter
Number Span test, LNS [33]), Verbal Learning (the
revised Hopkins Verbal Learning Test; HVLT-R, imme-
diate recall [34]), Visual Learning (the revised Brief
Visuospatial Memory Test; BVMT-R [35]), Reasoning/
Problem Solving (The Mazes test; Neuropsychological
Assessment Battery, NAB [36]), and Social Cognition (the
Managing Emotions part of the Mayer-Salovey-Caruso
Emotional Intelligence Test; MSCEIT [37]). In addition, a
Composite sum score is calculated across the seven
domains.
As there are no norms for the MCCB scores of tests
respondents above the age of 59, our results are reported
as T scores with a mean of 50 and an SD of 10. Due to
excessive fatigue, three of the patients did not perform
the MSCEIT test and nine of them did not perform the
CPT-IP test. This is indicated in Tables 3 and 4.
After the completion of the MCCB, the patients filled
in the Everyday Memory Questionnaire (EMQ) [38],
assessing practical attention and memory functions in 28
items.
Statistics
All statistical analyses were performed with IBM SpSS
Statistics version 22. Group differences in neurocognitive
function were analyzed with ANOVAs with effect sizes
reported as partial eta squared (η2). In the patient group,
the relationships between the MADRS score, the EMQ
score and the cognitive function scores were studied
with Pearson’s correlations.
Results
Compared to the control group, the depression group
performed significantly worse on all neurocognitive tests.
The effect sizes were largest for the assessments of
Speed of Processing and Reasoning/Problem solving,
with the patient group performing at a level 1.5–2.0 SDs
below the control mean (Table 3).
We chose a cut-off point of 1.5 SD below the control
mean as a sign of impairment. The same cut-off point
was chosen by Kessler et al. [7], facilitating the compari-
son of these two studies of the Norwegian MCCB in
depression disorders. When using this cutoff-point, the
level of impairment among the depression patients were
as follows: Speed of Processing: 58.0 %, Attention/
Vigilance: 25.0 %, Working Memory: 21.0 %, Verbal
Learning: 24.0 %, Visual Learning: 27.0 %, Reasoning/
Problem Solving: 52.0 %, and Social Cognition: 27.0 %.
In order to control for the possible influence of bipolar
disorder, anxiety disorders, and previous treatment with
ECT on the test results, these variables were entered
into the ANOVAs as covariates separately. This proced-
ure did not alter the statistical results.
Table 2 Clinical characteristic of the depression group (n = 33)
Years since first onset of depression 18.4 (SD 11.2, range 3–40)
MADRS score 33.5 (SD 7.7)






Years since onset, MADRS score, and EMQ score in mean. CDD: Calculated
dose of medication based on the prescribed dosage divided by the defined
daily dosage
Table 3 Neurocognitive scores of the MCCB (T scores) in
depression patients (n = 24–33) and healthy controls (n = 33)
Depression Controls F η2
Speed of Processing 45.4 (8.5) 54.6 (4.9) 28.51 *** .31
TMT-A 45.2 (11.5) 54.8 (4.6) 20.07 *** .24
BACS 44.4 (9.2) 55.6 (7.4) 29.14 *** .31





52.3 (9.3) 4.29 * .07
Working Memory 46.9 (8.8) 53.1 (7.0) 10.24 ** .14
SS-WMS 46.2 (10.1) 53.8 (8.4) 11.20 *** .15
LNS 47.6 (11.5) 52.4 (7.6) 4.04 * .06
Verbal Learning
(HVLT-R)
47.2 (10.2) 54.8 (9.1) 5.47 * .08
Visual Learning
(BVMT-R)
47.1 (11.2) 52.9 (7.8) 6.18 * .09
Reasoning/Problem Solving
(Mazes)





53.4 (9.2) 8.83 *** .13
Composite Score 48.4 (5.4)
(n = 24)
53.6 (4.2) 16.30 *** .23
Neurocognitive scores in mean (SD). F: Significance test of group differences.
***: p < .001, **: p < .01, *: p < .05. η2 : effect size
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The correlation analyses revealed several small to
moderate significant associations between depression
symptom severity and neurocognitive function. The cor-
relation between MADRS and EMQ was non-significant
(Table 4).
A series of similar analyses were run with EMQ and the
MCCB test results. None of these correlations reached
statistical significance, and there were no discernible non-
significant trends in the statistical results (ps from .98,
TMT-A, to .09, BVMT-R) (data not shown) (see Add-
itional file 1).
Discussion
To our knowledge, this is the first study of MCCB test
performance in relation to depressive symptom level and
subjective cognitive complaints in MDD patients.
On all the tests of the MCCB, the patient group was
outperformed by the healthy control group. The largest
group differences were found for Speed of Processing
and Reasoning/Problem Solving. As the test used to assess
Reasoning/Problem Solving domain is speed based, our
results support other findings of psychomotor speed being
strongly affected in depression disorders [1–3, 7, 13, 39].
Regarding the pattern of neurocognitive dysfunction,
there are certain differences between our study and
other relevant studies in this field. Rund et al. [13] found
larger impairments in verbal learning and working mem-
ory compared to us. However, they used related, but
different tests than we did, as well as more tests per
domain.
The MCCB tests responses reported in the Kessler et
al. [7] study were highly similar to ours. Therefore, our
results suggest that the MCCB is applicable for MDD as
well as for bipolar disorders.
According to our cut-off point of 1.5 SD below the
control mean, at least one fifth of our patients demon-
strated neurocognitive scores that indicate clinical levels
of impairment in all domains, and in Speed of Processing
and Reasoning/Problem Solving, more than half were clin-
ically impaired. These figures are higher than in the Rund
et al. [13] study, probably because our patients had been
classified as treatment-resistant and thus more severely ill.
Moreover, our percentages of impairment are slightly
higher than those of the Kessler et al. [7] study, likely due
to a combination of divergent number of participants as
well as different diagnoses within the depression disorder
spectrum.
Our patient group was heterogeneous in terms of the
presence of symptoms of bipolar disorder type II and
psychosis. Moreover, some of the patients had previously
been treated with ECT. However, the statistical control
for these variables did not alter the above results.
The severity of depression symptoms was significantly
correlated with most of the neurocognitive tests. This
contrasts with the findings of Kessler et al. [7], who re-
ported no such associations in bipolar I and II disorder
patients. However, the different diagnostic characteristics
of these two studies may explain the divergent results.
Neither in the Rund et al. [13] study of depressed pa-
tients was there any significant relations between symp-
tom load and cognitive test results, although this could
be explained by their employment of different assess-
ment methods to ours.
We found no significant relationship between subject-
ively reported cognitive complaints and MCCB perform-
ance. This is in accordance with other reports of such
discrepancy [15]. This result may reflect a general ten-
dency for pessimism and self-deprecation in depressed
individuals. However, the neuropsychological laboratory
tests may lack the ecological validity necessary for tap-
ping experiences of cognitive problems in everyday life
[16]. Moreover, the test situation per se is different from
one’s private life at work or at home. During neuro-
psychological assessment, one is usually able to muster
the effort and motivation to perform the tests as a func-
tion of having volunteered for the research project and
being given detailed instructions by the test technician,
while there may be little reason for concentration and
effort when one is alone at home.
In order to obtain a complete picture of the relation-
ship between subjective complaints and objective test
performance, the EMQ should be administered to the
control group as well. The fact that this was not done is
a limitation of the present study.
Strenghts and limitations
The major strengths of this study are our pairwise
matched samples and the use of a comprehensive, inter-
nationally validated neurocognitive test battery with
strong psychometric properties.
The major limitation is the relatively small samples.
Consequently, we were not able to compare the patients
with MDD alone to those with symptoms of bipolar
disorder II or psychosis. However, the statistical con-
trol we performed indicated that these added factors
Table 4 Correlations of the relationship between depression severity and cognitive variables in the depression group (n = 24–33)
EMQ TMT-A BACS Fluency SS-WMS LNS HVLT-R BVMT-R Mazes MSCEIT CPT-IP
MADRS -.33 -.19 -.38 * -.48 ** -.24 -.50 ** -.52 ** -.37 * -.01 -.47 ** -.17
**: p < .01, *: p < .05 (2-tailed)
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had no significant effect on neurocognitive function.
Moreover, our heterogeneous patient group is a typical
naturalistic sample, and our findings are probably clinic-
ally valid.
Another limitation is the lack of gender balance, as
there were twice as many women than men in our sam-
ples. The gender differences in MCCB performance in
Norway are not large among healthy respondents [25],
but there is a lack of information on possible gender dif-
ferences in responses among depressed individuals.
Third, the patient sample consisted of hospitalized
individuals awaiting ECT for severe treatment-resistant
depression. Possibly, our results may not generalize to
outpatients or less severely depressed people.
Fourth, several different clinicians were involved in the
diagnostic process. The patients were severely ill, and
the decision to commence ECT was sometimes made so
rapidly that the diagnostic process could not be under-
taken by one and the same clinician. We did, however,
rely on information from the patients’ journals as well as
the diagnostic interviews to ascertain the main diagnosis
of MDD.
A final limitation concerns the use of the MCCB. This
battery was assembled and validated for schizophrenia
spectrum disorders, and may not be the optimal way of
assessing cognitive function in MDD. Most of the
MCCB studies in non-schizophrenia samples have been
conducted with bipolar disorder patients, and although
this battery seems applicable in this group [6], it is rec-
ommended that more executive function tests are added
to the MCCB in order to capture the full extent of cog-
nitive dysfunction in bipolar disorders [9]. In unipolar
depression, an internationally validated consensus bat-
tery of tests of cognitive deficits is currently lacking. The
cognitive deficits in MDD are assumed to be less severe
compared to those of bipolar disorders and schizophre-
nia [40]. Possibly, the MCCB is not sensitive enough to
detect all of the more subtle cognitive impairments in
this disorder. Moreover, although we obtained distinctive
neurocognitive profiles in our depression patients and
healthy controls, our samples were small. Our conclu-
sions must be regarded as tentative pending future stud-
ies with larger samples.
Conclusions
The MCCB was able to separate the neurocognitive
profile of the current depression patients from that of
the healthy controls. There was a general cognitive
deficit in MDD patients compared to controls, with
at least one fifth of the patients demonstrating im-
pairment across domains. Psychomotor speed functions
were most severely affected. This cognitive dysfunction
may be partly explained by depression intensity. There
were no significant relationship between subjective
cognitive complaints and objective neuropsychological
test results.
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